Source: https://www.reanimatology.com/rmt/article/view/1089
Timestamp: 2019-04-20 08:34:14+00:00

Document:
1. King R. J., Clements J. A. Surface active materials from dog lung: composition and physiological correlations. Am. J. Physiol. 1972; 223: 715—726.
2. Avery M. E., Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am. J. Dis. Child. 1959; 97: 517—523.
3. Gross N. K., Barnes E., Narine K. R. Recycling of surfactant in black and beige mice: pool sizes and kinetics. J. Appl. Physiol. 1988; 64: 1027—1025.
4. Bangham, A. D. Artificial lung expanding compound (ALECtm). In: Lasic, Papahajopoulos, (eds.) Medical applications of liposomes: 1998: Elsevier science. 455—452.
5. van Iwaarden F. J., van Golde L. M. J. Pulmonary surfactant and lung defense. In: Robertson B., Taeusch H. W., (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: 1995: Marcel Dekker Inc.; 84. 75—84.
6. Ashbaugh D. G., Bigelow D. B., Petty T. L. et al. Acute respiratory distress in adults. Lancet 1967; 2: 319—323.
7. Lewis J. F., Jobe A. H. Surfactant and the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 1993; 147: 218—233.
8. Schmidt R., Meier U., Yabut-Perez M. et al. Alteration of fatty acid profiles indifferent pulmonary surfactant phospholipids in acute respiratory distress syndrome and pneumonia. Am. J. Resp. Crit. Care Med. 2001; 163: 95—100.
9. Baughman R. P., Stein E., MacGee J. et al. Changes in fatty acids in phospholipids of the bronchoalveolar fluid in bacterial pneumonia and in adult respiratory distress syndrome. Clin. Chem. 1984; 30: 521—525.
10. Baughman R. P., Sternberg R., Hull W. et al. Decreased surfactant protein A in patients with bacterial pneumonia. Am. Rev. Respir. Dis. 1987; 147: 653—658.
11. Gunther A., Siebert C., Schmidt R. et al. Surfactant alterations in severe pneumonia, ARDS and cardiogenic lung edema. Am. J. Resp. Crit. Care Med. 1996; 153: 176—184.
12. Lewis J., Veldhuizen R. The role of surfactant in pneumonia and sepsis. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 55—57.
13. von Bredow C., Birrer P., Griese M. Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur. Respir. J. 2001; 17: 716—724.
14. Griese M., Birrer P., Demirsoy A. Pulmonary surfactant in cystic fibrosis. Eur. Respir. J. 1997; 10: 1983—1997.
15. McCormack F. X., King T. E., Voelker D. R. et al. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage content of surfactant protein A. Am. Rev. Respir. Dis. 1991; 144: 160—169.
16. Robinson P. S., Watters L. C., King T. E. et al. Idiopathic pulmonary fibrosis. Abnormalities in the bronchoalveolar lavage fluid phospholipids. Am. Rev. Respir. Dis. 1988; 137: 585—592.
17. Oyarzun M. J., Stevens P., Clemens J. A. Effect of lung collapse on alveolar surfactant in rabbits subjected to unilateral pneumothorax. Exp. Lung Res. 1989; 15: 90—96.
18. Hallman M., Maasita P., Kivisaari L. et al. Changes in surfactant in bronchoalveolar lavage fluid after hemithorax irradiation in patients with mesothelioma. Am. Rev. Respir. Dis. 1990; 141: 998—1007.
19. Ackerman S. J., Kwatia M. A., Doyle C. B. et al. Hydrolysis of surfactant phospholipids catalyzed by phospholipase A2 and eosinophil lysophospholipases causes surfactant dysfunction: a mechanism for small airway closure in asthma. Chest 2003; 123: 355—361.
20. Cheng G., Ueda T., Numao T. et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur. Respir. J. 2000; 16: 831—835.
21. Haczku A., Atochina E. N., Tomer Y. et al. The late asthmatic response is linked with increased surface tension and reduced surfactant protein B in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 2002; 283: 755—760.
22. Hohlfeld J., Ahlf K., EnhorningG. et al. Dysfunction of pulmonary surfactant in asthmatics after segmental allergen challenge. Am. J. Respir. Crit. Care Med. 1999; 159: 1803—1809.
23. Hohlfeld J. M., Schmiedl F., Erpenbeck V. J. et al. Eosiniphil cationic protein (ECP) alters pulmonary structure and function in asthma. J. Allergy Clin. Immunol. 2004; 113: 496—502.
24. Wang J. Y., Shieh C. C., Yu C. K. et al. Allergen-induced bronchial inflammation is associated with decreased levels of surfactant proteins A and D in a murine model of asthma. Clin. Exp. Allergy 2001; 31: 652—662.
25. Wright S. M., Hockey P. M., Enborning G. et al. Altered airway surfactant phospholipids composition and reduced lung function in asthma. J. Appl. Physiol. 2000; 89: 1283—1292.
26. Devendra G. Spragg R. G. Lung surfactant in subacute pulmonary disease. Respiratory Res. 2002; 3: 19—30.
27. Günther A. et al. Surfactant abnormalities in idiopathic pulmonary fibrosis, hypersensitivity pneumonitis and sarcoidosis. Eur. Respir. J. 1999; 14: 565—576.
28. Ерохин В. В. Морфофункциональное состояние клеток легких при туберкулезном воспалении. В кн.: Ерохин В. В., Романова Л. К. (ред.) Клеточная биология легких в норме и при патологии. Руководство для врачей. М.: Медицина; 2000. 496—518.
29. Rosenberg O., Bautin A., Osovskich V. et al. Surfactant therapy for acute and chronic lung diseases. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 78—78.
30. Fujiwara T., Maeta H., Chida S. et al. Artificial surfactant therapy in hyaline membrane disease. Lancet 1980; 1: 55—59.
31. Lachmann B. Surfactant replacement in acute respiratory failure: Animal studies and first clinical trials. In.: Lachmann B. (ed.) Surfactant replacement тherapy. N. Y.: Springer-Verlag; 1987. 212—220.
32. Spragg R. G. Current status of surfactant treatment of ARDS/ALI. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 88—90.
33. Gregory T. J., Gadek J. E., Weiland J. E. et al. Survanta supplementation in patients with acute respiratory distress syndrome (ARDS). Am. J. Resp. Crit. Care Med. 1994; 49: 125—131.
34. Rosenberg O. A., Bautin A. E., Osovskich V. V. et al. When to start surfactant therapy (ST-therapy) of acute lung injury? Eur. Respir. J. 2001; 18 (Suppl. 38): 153, 7s.
35. Anzueto A., Baughman R., Guntupalli K. K. et al. Aerosolized surfactant in adults with septic-induced acute respiratory distress syndrome. N. Eng l. J. Med. 1996; 334: 1417—1421.
36. Bonсˆuk=Dayanikli P., Taeusch W. H. Essential and nonessential constituents of exogenous surfactants. In: Robertson, B. Taeusch, H. W. (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. 84. N. Y.; 1995: Marcel Dekker, Inc. 217—238.
37. Günther A., Ruppert C., Schmidt R. et al. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir. Res. 2001; 2 (6): 353—364.
38. Sanders R. L. The composition of pulmonary surfactant. In: Farrell P. M. (ed.) Lung development: вiological and сlinical рerspectives. N. Y.: Academic Press; 1982. 1. 193—210.
39. Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am. Rev. Respir. Dis. 1988; 138: 990—998.
40. Persson A., Chang D., Rust D. et al. Purification and biochemical characterization of CP4 (SP-D), a collagenous surfactant-associated protein. Biochemistry 1989; 28: 6361—6367.
41. Weaver T. E., Whitsett J. A. Function and regulation of expression of pulmonary surfactant-associated proteins. Biochem. J. 1991; 273: 249—264.
42. Goerke J., Clements J. A. Alveolar surface tension and lung surfactant. In: Handbook of рhysiology. The Respiratory system. Mechanics of вreathing. 3 Am. Phisiol. Soc. Bethesda; 1986. Sect. 3. P I. 247—263.
43. Schurch S., Bachofen H. Biophysical aspects in the design of a therapeutic surfactant. In: Rodertson B., Taeush H. W., (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. 84. N. Y.: Marcel Dekker Inc; 1995. 3—26.
44. Horie T., Hildebrandt J. Dynamic compliance, limit cycles and static equilibria of excised cat lung. J. Appl. Physiol. 1971; 31: 423—428.
45. Mead J., Collier C. Relation of volume history of lungs to respiratory mechanics in anesthetized dogs. J. Appl. Physiol. 1959; 14: 669—675.
46. Rosenberg O., Seiliev A., Zhuikov. Lung Surfactant: Correlation beween biophysial charactrisic, composition, and therapeutic effiacy. In: Gregory Gregoriadis, (ed.) Liposome тechnology. Taylor and Francis; 2006. 3ed, 3, сh. 17. 317—345.
47. Bachofen H. et al. Relations among alveolar surface tension, surface area, volume and recoil pressure. J. Appl. Physiol. 1987; 62: 1878-1891.
48. Schürch S., Goerke J., Clements J. A. Direct determination of volumeand time-dependence of alveolar surface tension in excised lungs. Proc. Natl. Acad. Sci. USА 1978; 75: 3417—3420.
49. Bachofen H. et al. Experimental hydrostatic pulmonary edema in rabbit lungs. Morphology. Am. Rev. Respir. Dis. 1993; 147: 989—996.
50. Bachofen H., Schürch, S., Weibel I. R. Experimental hydrostatic pulmonary edema in rabbit lungs. Barrier lesions. Am. Rev. Respir. Dis. 1993; 147: 997—1006.
51. LaForce F. M., Kelley W. J., Huber J. L. Inactivation of staphylococci by alveolar macrophages with preliminary observations on the importance of alveolar lining material, Am. Rev. Respir. Dis. 1973; 108: 783—789.
52. Wollmer P., Jonson B., Lachmann B. Evaluation of lung permeability. In: Robertson B., Taeusch, H. W., (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.; 1995; 84. 199—215.
53. Hohlfeld J., Fabel H., Hamm H. The role of pulmonary surfactant in obstructive airway disease. Eur. Respir. J. 1997; 10: 482—491.
54. Hohlfeld J. M. The role of pulmonary surfactant in asthma. Major components of surfactant (functions). Respir. Res. 2002; 3: 4—12.
55. Bates S. R., Ibach P. B, Fisher A. B, Phospholipids co-isolated with rat surfactant protein C account for the apparent protein-enhanced uptake of liposomes into lung granular pneumocytes. Exp. Lung Res. 1989; 15: 695—708.
56. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1998; 1408: 79—89.
57. Cocksgutt A., Absolom D., Possmayer F. The role of palmitic acid in pulmonary surfactant: enhancement of surface activity and prevention of inhibition by blood proteins. Biochim. Biophys. Acta 1991; 1085: 248—256.
58. Holm B. A., Venkitaraman A. R., Enchorning G. et al. Biophysical inhibition of synthetic lung surfactants. Chem. Phys. Lipids 1990; 52: 243—250.
59. Longo M. L., Bisango A. M., Zasadzinski J. et al. A function of lung surfactant protein SP-B. Science 1993; 261: 453—456.
60. Tanaka, Y., Takei T., Aiba T. et al. Development of synthetic lung surfactants. J. Lipid Res. 1986; 27: 475—485.
61. Orgeig S., Daniels C. B. The roles of cholesterol in pulmonary surfactant: insights from comparative and evolutionary studies. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2001; 129: 75—89.
62. Bunt J. E. H. Surfactant therapy stimulates endogenous surfactant synthesis in premature infants. Crit. Care Med. 2000; 28: 3383.
63. Ikegami M. SP-B protects lung from inflammation. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 45—47.
64. Miles P. R., Bowman L., Rao K. M. et al. Pulmonary surfactant inhibits LPS-induced nitric oxide production by alveolar macrophages. Am. J. Physiol. 1999; 276 (1P. 1): 186—196.
65. van Iwaarden J. F., Claassen E., Jeurissen S. H. et al. Alveolar macrophages, surfactant lipids, and surfactant protein B regulate the induction of immune responses via the airways. Am. J. Respir. Cell Mol. Biol. 2001; 24 (4): 452—458.
67. Crouch E., Wright. J. R. Surfactant proteins A and D and pulmonary host defense. Ann. Rev. Physiol. 2001; 63: 521—534.
68. Phelps D. S. Surfactant regulation of host defense function in the lung: a question of balance. Pediatr. Pathol. Mol. Med. 2001; 20: 269—274.
69. Erpenbeck V. J., Malherbe D. C., Sommer S. et al. Surfactant protein D regulates phagocytosis of Grass pollen-derived starch granules by alveolar macrophages. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 31—32.
70. Hawgood S. The hydrophilic surfactant protein SP-A: Molecular biology, structure and function. In: Robertson B., Van Golde L. M. G., Batenburg J. J., (eds.) Pulmonary surfactant: From molecular biology to clinical practice. Amsterdam: Elsevier; 1992. 33—54.
71. Wright J. R. Immunomodulatory functions of surfactant. Physiol Rev. 1997; 77: 931—942.
72. Wright J. R. Surfactant: A pulmonary link between innate and adaptive immunity. Appl. Cardiopulm. Pathophysiol. 2004; 13: 104—105.
73. Clark H., Palaniyar N., Strong P. et al. Surfactant protein reduces alveolar macrophage apoptosis in vivo. J. Immunol. 2002; 169 (6): 2892—2899.
74. Clark H. W., Palaniyar N., Hawgood S. et al. A recombinant fragment of human surfactant protein D reduces alveolar macrophage apoptosis and pro-inflammatory cytokones in mice developing pulmonary emphysema. Ann. N. Y. Acad. Sci. 2003; 1010: 113—116.
75. Kaplan J. H., Casey J. A., Savani R. C. et al. Differential response of collectin deficient mouse models to bleomycin induced lung injury. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 51—52.
76. Lewis J., Veldhuizen R. The role of surfactant in the pathophysiology of acute lung injury. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 53—55.
77. Clark J. C., Wert S. E., Bachurski C. J. et al. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl. Acad. Sci. USA 1995; 92 (17): 7794—7798.
78. Nogee L. M., Garnier G., Dietz H. C. et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J. Clin. Invest. 1994; 93 (4): 1860—1863.
79. Melton K. R., Nesslein L. L., Ikegami M. et al. SP-B deficiency causes respiratory failure in adult mice. Am. J. Physiol. 2003; 285: 543—549.
80. Cochrane C. G. A critical examination of the role of SP-B in alveolar expansion, Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 27—29.
81. Cruz A., Vazquez L., Bernardinjo J. et al. Analysis by scanning force microscopy of the micro- and nano-structure of Langmuir-Blodgett pulmonary surfactant films. Appl. Cardiopulm. Pathophysiol. 2004; 13: 30—31.
82. Cruz A. et al. Effect of pulmonary surfactant protein SP-B on the micro- and nanostructure of phospholipids films. Biophys. J. 2004; 86: 308—310.
83. Na Nkorn P., Flach C. R., Mendelsohn R. et al. The influence of truncated surfactant-protein C (SP-C17) on the surface properties of lipid-monolayers at the air-water interface. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 62—63.
84. Weaver T. E., Conkright J. J. Function of surfactant proteins B and C. Annu. Rev. Physiol. 2001; 63: 555—578.
85. Cotton R. B., Olsson T. Lung mechanics in respiratory distress syndrome. In: Robertson B., Taeusch H. W. (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.; 1995; 84. 121—150.
86. Floros J., Veletza V., Kotikalapudi P. et al. Dinucleotide repeats in the human surfactant protein B gene and respiratory distress syndrome. Biochem. J. 1995; 305: 583—590.
87. Nogee L. M., deMello D. E., Dehner L. P. et al. Deficiency of pulmonary surfactant protein B in alveolar proteinosis. N. Engl. J. Med. 1993; 328: 406—410.
88. Рейниш М. С., Розенберг О. А. Быстрый метод определения фосфолипидов в амниотической жидкости. Лаб. дело 1978; (2): 98—100.
89. Bernard G. R. et al. The American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am. J. Respir. Crit. Care Med. 1994; 149: 818—821.
90. Gregory T. J., Longmore W. J., Moxley M. A. et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J. Clin. Invest. 1991; 88: 1976—1981.
91. Hallman M., Spragg R., Harrell J. H. et al. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity and plasma myoinositol. J. Clin. Invest. 1982; 70: 673—683.
92. Pison U., Seeger W., Buchhorn R. et al. Surfactant abnormalities in patients with respiratory failure after multiple trauma. Am. Rev. Respir. Dis. 1989; 140: 1033—1039.
93. Green K. E., Wright J. R., Steinberg K. R. et al. Serial changes in surfactant-associated proteins in lung and serum before and after onset of ARDS. Am. J. Resp. Crit. Care Med. 1999; 160: 843—1850.
94. Lewis J. F., Veldhuizen R., Possmayer F. et al. Altered alveolar surfactant is an early marker of acute lung injury in septic adult sheep. Am. J. Resp. Crit. Care Med. 1994; 150 (1): 123—130.
95. Veldhuizen R., McCaig L. A., Akino T. et al. Pulmonary surfactant sub-fractions in patients with the acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 1995; 152: 1867—1871.
96. Cockshutt A. M., Weitz J., Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 1990; 29: 8424—8429.
97. Fuchimukai T., Fujiwara T., Takahashi A. Artificial pulmonary surfactant inhibition by proteins. J. Appl. Physiol. 1987; 62: 429—437.
98. Seeger W., Stohr G., Wolf H. R. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J. Appl. Physiol. 1985; 58: 326—338.
99. Holm B. A., Notter R. H. Effects of hemoglobin and cell membrane lipids on pulmonary surfactant activity. J. Appl. Physiol. 1987; 63: 1434—1442.
100. Seeger W., Thede C., Gunter A. et al. Surface properties and sensitivity to protein-inhibition of a recombinant apoprotein C-based phospholipids mixture in vitro comparison to natural surfactant. Biochim. Biophys. Acta 1991; 1081: 45—52.
101. Seeger W., Gunther A., Thede C. Differential sensitivity to fibrinogen inhibition of SP-C- vs. SP-B-based surfactants. Am. J. Physiol. 1992; 262: 286—291.
102. Venkitaraman A. R., Gunther A., Thede C. et al. Biophysical inhibition of synthetic phospholipid-lung surfactant apoprotein admixtures by plasma proteins. Chem. Phys. Lipids 1991; 57: 49—57.
103. Gunther A., Kalinovski M., Rosseau S. et al. Surfactant incorporation markedly alters mechanical properties of a fibrin clot. Am. J. Respir. Cell Mol. Biol. 1995; 13: 712—718.
104. Seeger W., Elssner A., Gunter A. et al. Lung surfactant phospholipids associate with polymerizing fibrin: loss of surface activity. Am. J. Respir. Cell Mol. Biol. 1993; 9: 213—220.
105. Gunther A., Markart P., Kalinowski M. et al. Cleavage of surfactant-incorporated fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity. Am. J. Respir. Cell Mol. Biol. 1999; 21: 738—745.
106. Schermuly R. T., Gunter A., Ermert M. et al. Conebulization of surfactant and urokinase restores gas exchange in perfused lungs with alveolar fibrin formation. Am. J. Physiol. Lung Cell Mol. Physiol. 2001; 280: 792—800.
107. Baker C. S., Evans T. W., Randle B. J. et al. Damage to surfactant-specific protein in acute respiratory distress syndrome. Lancet 1999; 353: 1232—1235.
108. Pison U., Obertacke U., Brand M. et al. Altered pulmonary surfactant in uncomplicated and septicemia-complicated courses of acute respiratory failure. J. Trauma 1990; 30: 19—26.
109. Petty T. L., Silvers G. W., Paul G. et al. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome. Chest 1979; 75: 571—574.
110. Günter A., Schmidt R., Harold J. at al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact of biophysical and biochemical surfactant properties. Eur. Respir. J. 2002; 19: 797—804.
111. Gregory T. J., Steinberg K. R., Spragg R. et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Resp. Crit. Care Med. 1997; 155: 1309—1315.
112. Hohlfeld J. M. Potential role of surfactant in asthma. Appl. Cardiopulm. Pathophysiol. 2004; 13 (1): 44—45.
113. Kurashima K., Fuimura M., Matsuda T., Kobauashi T. Surface activity of sputum from acute asthmatic patients. Am. J. Respir. Crit. Care Med. 1997; 155: 1254—1257.
114. Cheng G. et al. Compositional and functional changes of pulmonary surfactant in a guinea-pig model of chronic asthma. Respir. Med. 2001; 95: 180—186.
115. Liu M., Wang L., Enhorning G. Surfactant dysfunction develops when the immunized guinea-pig is challenged with ovalbumin aerosol. Clin. Exp. Allergy 1995; 25: 1053—1056.
116. Morley C. J. et al. Dry artificial lung surfactant and its effect on very premature babies. Lancet 1981; 1: 64—66.
117. Revak S. D., Merritt T. A., Hallman M. et al. The use of synthetic peptides in the formation of biophysically and biologically active pulmonary surfactants Pediatr. Res. 1991; 29: 460-465.
118. Häfner D., Germann P. =G., Hauschke D. Effects of rSP-C surfactant on oxygenation and histology in a rat-lung-lavage model of acute lung injury. Am. J. Respir. Crit. Care Med. 1998; 158: 270—276.
119. Баутин А. Е., Осовских В. В., Хубулава Г. Г. и др. Многоцентровые клинические испытания сурфактанта-BL для лечения респираторного дистресс-синдрома взрослых. Клинические исследования лекарственных средств в России 2002; (2): 18—23.
120. Curstedt T., Jornvall H., Berggren P. et al. Artificial surfactant based on different hydrophobic low-molecular — weight proteins. In: Lachmann B. (ed.) Surfactant replacement therapy in neonatal and adult respiratory distress syndrome. Berlin: Springer-Verlag; 1988. 332—337.
121. Hallman M. , Meritt T. A., Schneider H. et al. Isolation of human surfactant from amniotic fluid and pilot study of its efficacy in respiratory distress syndrome. Pediatrics 1983; 71: 473—482.
122. Розенберг О. А., Данилов Л. Н., Волчков В. А. и др. Фармакологические свойства и терапевтическая активность отечественных препаратов легочного сурфактанта. Бюл. эксперим. биол. и мед. 1998; 126 (10): 455—458.
123. Шаламов В. Ю., Веселова Н. Б., Миленин О. Б. и др. Эффективность отечественного сурфактанта из амниотической жидкости человека — Сурфактант-HL в комплексе интенсивной терапии новорожденных с РДС. Рос. вестн. перинатологии и педиатрии 1999; 44 (4): 29—34.
124. Розенберг О. А., Сейлиев А. А., Волчков В. А. и др. Легочные сурфактанты природного происхождения для лечения синдрома дыхательных расстройств новорожденных и взрослых. В кн.: Материалы конф. Актуальные проблемы создания новых лекарственных препаратов природного происхождения. СПб. — Валаам; 1998. 81—85.
125. Notter R. H., Egan E. A., Kwong M. S. et al. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique and gestational age. Pediatr. Res. 1985; 19: 569—574.
126. Yu S. et al. Bovine pulmonary surfactant: chemical composition and physical properties. Lipids 1983; 18: 522—526.
127. Bligh E. G., Dayer W. J. A. rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 1959; 37: 911—916.
128. Bernhard W., Mottaghian J., Gebert A et al. Commercial versus native surfactants surface activity, molecular components, and the effect of calcium. Am. J. Respir. Crit. Care Med. 2000; 162: 1524—1533.
129. Rudiger M., Tolle A., Meier W. et al. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am. J. Physiol. Lung Cell. Mol. Physiol. 2005; 288: L379—L380.
130. Taeusch H. W., Karen L. U., Ramierez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacol. Sin. 2002; 11: 15—18.
131. Gunther A., Seeger W. Resistance to surfactant inactivation. In: Robertson B., Taeusch H. W. (eds.) Surfactant therapy for lung disease. Lung biology in health and disease. N. Y.: Marcel Dekker, Inc.; 1995; 84. 269—279.
132. Seeger W., Grube C., Gunter A. et al. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur. Respir. J. 1993; 6: 971—977.
133. Arnold C. et al. A multicenter, randomized trial comparing synthetic surfactant with modified bovine surfactant extract in the treatment of neonatal respiratory distress syndrome. Pediatrics 1996; 97: 1—11.
134. Halliday H. L. Natural vs synthetic surfactant in neonatal respiratory distress syndrome Drugs 1996; 51: 226—232.
136. Мостовой А. В., Наумов Д. Ю. Профилактическое и терапевтическое введение куросурфа недоношенным новорожденным с низкой и экстремально низкой массой тела с последующим переводом на неинвазивную вентиляцию легких: влияние на неврологический исход (пилотное исследование). В кн.: Материалы 5 Съезда Рос. ассоциации специалистов перинатальной медицины. М.; 2005. 134—136.
137. Русанов С. Ю., Черданцева Г. А., Антонов А. Г. и др. Сравнительная эффективность эндотрахеального ингаляционного и микроструйного введения сурфактанта-BL в комплексном лечении тяжелого РДС у недоношенных новорожденных. Рос. вестн. перинатологии и педиатрии 2003 (1): 26—31.
138. Романенко К. В., Романенко В. А., Аверин А. П. и др. Оценка эффективности отечественного сурфактанта в комплексном лечении дыхательной недостаточности у новорожденных детей. Рос. вестн. перинатологии и педиатрии 2001; (1): 22—25.
139. Затовка Г. Н., Дугинова С. А., Сафаров А. А. и др. Лечение респираторного дистресс-синдрома у новорожденных с применением сурфактанта-BL. Анестезиология и реаниматология 2006; (1): 38—43.
140. Lachmann B. Open up the lung and keep the lung open. Intensive Care Med. 1992; 13: 319—324.
141. Walmrath D., Grimminger F., Pappert D. et al. Bronchoscopic administration of bovine natural surfactant in ARDS and septic shock: impact on gas exchange and haemodynamics. Eur. Respir. J. 2002; 19: 805—810.
142. Spragg R. G., Gilliard N., Richmann P. et al. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 1994; 105: 195—202.
143. Walmrath D., Gunter A., Ghofrani H. A et al. Bronchoscopic surfactant administration in patients with severe adult respiratory distress syndrome and sepsis. Am. J. Resp. Crit. Care Med. 1996; 154: 57—62.
144. Willson D. F., Zaritsky A., Bauman L. A et al. Instillation of calf lung surfactant extract (Calfactant) is beneficial in pediatric acute hypoxemic respiratory failure. Crit. Care Med. 1999; 27: 188—195.
145. Spragg R. G., Zewis J. F., Walmrathe H.-D. et al. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. 2004; 351: 884—889.
146. Цыбулькин Э. К., Розенберг А. O., Ceйлиев А. А. и др. Опыт применения отечественного препарата легочного сурфактанта для лечения синдрома дыхательных расстройств взрослых и тяжелых пневмоний у детей. Анестезиология и реаниматология 1999; (2): 26—32.
147. Розенберг О. А., Баутин А. Е., Осовских В. В. и др. Сурфактант-терапия синдрома острого повреждения легких. В кн.: 2 Междунар. конгр. по респираторной поддержке. Красноярск; 2005. 97—98.
148. Anzueto A., Baughman R. P., Yuntupalli K. K. et al. Aerosolized surfactant in adults with septi-induced acute respiratory distress syndrome. N. Engl. J. Med. 1996; 334: 1417—1421.
149. Anzueto A. Exogenous surfactant in acute respiratory distress syndrome: more is better. Eur. Respir. J. 2002; 19: 787—789.
150. Wiswell T. E., Smith R. M., Katz L. B. et al. Bronchopulmonary segmental lavage with Surfaxin (KL4-Surfactant) for acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 1999; 160: 1188—1195.
151. Greenhalgh T. How to read a paper: The basics of evidence based medicine. 2nd ed. L.: BMJ Books; 2001.
152. Liolios A. Evidence-based medicine in intensive care unit. In: A debate 23rd. Int. sympos. of intensive care and emergency medicine. Progr. and abstracts. Brussels; 2003. 18—21.
153. Marini J. J. Evidence based medicine in intensive Care Unit. In: Ibid 18—21.
154. Marini J. J. Advances in the understanding of acute respiratory distress syndrome: summarizing a decade of progress. Curr. Opin. Crit. Care 2004; 10 (4): 265—271.
155. Osovskikh V., Seiliev A., Rosenberg O. Exogenous surfactant: a potent drug for gastric content aspiration? Eur. Respir. J. 2002; 20: 336—336.
156. Osovskikh V., Seiliev A., Rosenberg O. ARDSp and ARDSexp: different responses to surfactant administration. Eur. Respir. J. 2003; 22: 551—551.
157. Tarasenko M., Shpakov Ig., Kallistov D. et al. Surfactant therapy — the real chance to survive for patients with severe inhalation injury. Eur. Respir. J. 2004; 24, (Suppl. 48): 4127 (677 s).
158. Баутин А. Е., Хубулава Г. Г., Оссовских В. В., Розенберг О. А. Результаты применения природного легочного сурфактанта при респираторном дистресс-синдроме после операций на открытом сердце. Анестезиология и реаниматология 2003; (4): 55—57.
159. Козлов И. А., Попцов В. Н. Сочетанная терапия оксидом азота и сурфактантом-BL при остром респираторном дистресс-синдроме после операций с искусственным кровообращением. Общая реаниматология 2005; 1: 15—19.
160. Walmrath D., De Vaal J. B., Bruining H. P. et al. Treatment of ARDS with a recombinant SP-C (rSP-C) based synthetic surfactant. Am. J. Resp. Crit. Care Med. 2000; 161: A379.
161. Власенко А. В., Остапченко Д. А. Мороз B. B. и др. Применение сурфактанта-BL у взрослых больных с острым респираторным дистресс-синдромом различного генеза. Общая реаниматология 2005; 1: 21—29.
163. Mikawa K. et al. Selective intrabronchial instillation of surfactant in a patient with pneumonia: a preliminary report. Eur. Respir. J. 1993; 6: 1563—1566.
164. Dulkys Y. et al. Natural porcine surfactant augments airway inflammation after allergen challenge in patients with asthma. Am. J. Respi r. Crit. Care Med. 2004; 169: 578—581.
165. Kurashima K. A pilot study of surfactant inhalation in the treatment of asthmatic attack. Allerugi 1991; 40: 160—168.
166. Oetomo S. B. et al. Surfactant nebulization does not alter airflow obstruction and bronchial responsiveness to histamine in asthmatic children. Am. J. Respir. Crit. Care Med. 1996; 153: 1148—1153.
167. Ловачева О. В., Черниченко Н. В., Евгущенко Г. В. и др. Результаты применения препарата сурфактанта в комплексной терапии больных деструктивным туберкулезом легких. Проблемы туберкулеза и болезней легких 2006; (10): 12—17.
168. Erokhin V. V. Chenichenko N. V. Lepekha L. N. et al. Peculiarities of macrophagal composition of bronchial washings in destructive TB patients after using surfactant-BL (S-BL). Eur. Respir. J. 2003; 22: (Suppl. 40): 340.
169. Rosenberg O., Erochin V. O., Lovacheva O. V. et al. The application of the liposome form of lung surfactant (Surfactant-BL) for complex treatment of multi-drug resistant tuberculosis. Jn: 6th international conference Liposome advances. L. 2003. 61—62.
170. Anzueto A., Jubran A., Ohar J. A. et al. Effects of aerosolized surfactant in patients with stable chronic bronchitis: a prospective randomized controlled trial. JAMA 1997; 278: 1426—1429.
171. Lovacheva O. V., Nataly V., Chemichenko L. N. et al. Use of surfactantBL (S-BL) in complex treatment of pulmonary TB patients. Eur. Respir. J. 2003; 22: 521—521.

References: V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V. 
 V.